Corporate News

Comment on Share Price movement

25 January 2021

MyHealthChecked Plc (AIM: MHC), the personalised healthcare company, notes the increase in its share price this morning.

The Company refers to recent notifications on 23 November 2020, regarding the acquisition of The Genome Store Ltd; on 2 December 2020, confirming the   launch of the Company's genomic testing service and change of corporate name to reflect the Company's refined strategy; and 29 December 2020, which noted that the Company's COVID-19 testing service has been added to the UK Government's approved COVID-19 private testing providers list for General Testing, and the Test to Release for International Travel scheme introduced on 15 December 2020.

The Board is currently in the process of undertaking an equity fundraising to provide funds to allow the Company to develop its strategy and for working capital for the business.


A further announcement will be made in due course.

MyHealthChecked plc

Penny McCormick , Chief Executive Officer

via Walbrook PR

Maddy Kennedy, Chief Financial Officer


SPARK Advisory Partners Limited (NOMAD)

Tel: +44 (0)20 3368 3550

Neil Baldwin


Oberon Capital Ltd (Broker)

Tel: +44 (0)203 179 5344

Mike Seabrook

[email protected]


Walbrook PR Ltd (Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus

Mob: +44(0)7980 541 893



About MyHealthChecked PLC ( )

MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company with two diverse, customer-facing at-home testing brands in its portfolio:

MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests, now in development following the recent acquisition of The Genome Store. The tests will be made available on line, and would be viable for over the counter purchase.

The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts.

Mylo targets the personalized mobile health market, with a primary focus on hormone testing and increasing a woman's chances of naturally getting pregnant, and providing insight to unexplained infertility. The myLotus range of IVDs are CE-marked and are expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.

The myLotus range of IVDs are currently the UK's only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin ("hCG") hormone level during pregnancy.